Transformation of human ovarian surface epithelial cells by Krüppel-like factor 8

Oncogene

Volumn 33, Issue 1, 2014, Pages 10-18

  Lu, H ^a   Wang, X ^a   Urvalek, A M ^a   Li, T ^a   Xie, H ^b   Yu, L ^a   Zhao, J ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b FLORIDA HOSPITAL   (United States)

Author keywords

human ovarian cancer; human ovarian epithelial cells; KLF8; transformation

Indexed keywords

CYCLIN D1; DEUBIQUITINASE; KRUPPEL LIKE FACTOR; STAT3 PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CLONOGENIC ASSAY; CONTROLLED STUDY; CYCLIN D1 GENE; EPITHELIUM CELL; FEMALE; FIBROBLAST; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KRUPPEL LIKE FACTOR 8 GENE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE C MYC; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN KINASE B GENE; QUANTITATIVE ANALYSIS; RETROVIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAT3C GENE; SURVIVAL TIME; TISSUE MICROARRAY; UBIQUITIN SPECIFIC PROTEASE 44 GENE; WESTERN BLOTTING;

MUS MUSCULUS;

EID: 84891741065     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.545     Document Type: Article

References (55)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
2. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A et al. A genetically defined model for human ovarian cancer. Cancer Res 2004; 64: 1655-1663. (Pubitemid 38428686)
3. Rosen DG, Yang G, Bast Jr RC, Liu J. Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. Methods Enzymol 2006; 407: 660-676.
4. Yang G, Thompson JA, Fang B, Liu J. Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer. Oncogene 2003; 22: 5694-5701. (Pubitemid 37102706)
5. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 2002; 1: 53-62. (Pubitemid 41039176)
6. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992; 89: 9267-9271.
7. Cheng JQ, Jiang X, Fraser M, Li M, Dan HC, Sun M et al. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist Updat 2002; 5: 131-146. (Pubitemid 35033805)
8. Fang Q, Naidu KA, Zhao H, Sun M, Dan HC, Nasir A et al. Ascorbyl stearate inhibits cell proliferation and tumor growth in human ovarian carcinoma cells by targeting the PI3K/AKT pathway. Anticancer Res 2006; 26: 203-209. (Pubitemid 43206080)
9. Liu AX, Testa JR, Hamilton TC, Jove R, Nicosia SV, JQ Cheng. AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res 1998; 58: 2973-2977. (Pubitemid 28335073)
10. Yang H, He L, Kruk P, Nicosia SV, Cheng JQ. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer 2006; 119: 2304-2312. (Pubitemid 44546949)
11. Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ. AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem 2003; 278: 23432-23440. (Pubitemid 36830160)
12. Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000; 19: 2324-2330. (Pubitemid 30307208)
13. Zheng J, Mercado-Uribe I, Rosen DG, Chang B, Liu P, Yang G et al. Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle 2010; 9: 140-146.
14. Yue P, Zhang X, Paladino D, Sengupta B, Ahmad S, Holloway RW et al. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. Oncogene 2012; 31: 2309-2322.
15. Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 2003; 63: 3459-3463. (Pubitemid 36793020)
16. Shan W, Liu J. Epithelial ovarian cancer: focus on genetics and animal models. Cell Cycle 2009; 8: 731-735.
17. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68: 425-433. (Pubitemid 351380068)
18. Johnson NC, Dan HC, Cheng JQ, Kruk PA. BRCA1 185delAG mutation inhibits Aktdependent, IAP-mediated caspase 3 inactivation in human ovarian surface epithelial cells. Exp Cell Res 2004; 298: 9-16. (Pubitemid 38887302)
19. Yang F, Guo X, Yang G, Rosen DG, Liu J. AURKAand BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma. Mod Pathol 2011; 24: 836-845.
20. Yang G, Chang B, Yang F, Guo X, Cai KQ, Xiao XS et al. Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res 2010; 16: 3171-3181.
21. Zhou C, Huang P, Liu J. The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells. Biochem Biophys Res Commun 2005; 336: 952-960. (Pubitemid 41338360)
22. Zhou C, Liu J. Inhibition of human telomerase reverse transcriptase gene expression by BRCA1 in human ovarian cancer cells. Biochem Biophys Res Commun 2003; 303: 130-136. (Pubitemid 36338217)
23. Zhou C, Smith JL, Liu J. Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 2003; 22: 2396-2404. (Pubitemid 36560723)
24. Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003; 63: 1389-1397. (Pubitemid 36348722)
25. van Vliet J, Turner J, Crossley M. Human Kruppel-like factor 8: a CACCC-box binding protein that associates with CtBP and represses transcription. Nucleic Acids Res 2000; 28: 1955-1962. (Pubitemid 30229662)
26. Wang X, Lu H, Urvalek AM, Li T, Yu L, Lamar J et al. KLF8 promotes human breast cancer cell invasion and metastasis by transcriptional activation of MMP9. Oncogene 2011; 30: 1901-1911.
27. Wei H, Wang X, Gan B, Urvalek AM, Melkoumian ZK, Guan JL et al. Sumoylation delimits KLF8 transcriptional activity associated with the cell cycle regulation. J Biol Chem 2006; 281: 16664-16671.
28. Zhao J, Bian ZC, Yee K, Chen BP, Chien S, Guan JL. Identification of transcription factor KLF8 as a downstream target of focal adhesion kinase in its regulation of cyclin D1 and cell cycle progression. Mol Cell 2003; 11: 1503-1515. (Pubitemid 36776537)
29. Zhang P, Basu P, Redmond LC, Morris PE, Rupon JW, Ginder GD et al. A functional screen for Kruppel-like factors that regulate the human gamma-globin gene through the CACCC promoter element. Blood Cells Mol Dis 2005; 35: 227-235. (Pubitemid 41268658)
30. Wang X, Zheng M, Liu G, Xia W, McKeown-Longo PJ, Hung MC et al. Kruppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion. Cancer Res 2007; 67: 7184-7193. (Pubitemid 47206546)
31. Li JC, Yang XR, Sun HX, Xu Y, Zhou J, Qiu SJ et al. Up-regulation of Kruppel-like factor 8 promotes tumor invasion and indicates poor prognosis for hepatocellular carcinoma. Gastroenterology 2010; 139: 2146-2157.e12.
32. Urvalek AM, Lu H, Wang X, Li T, Yu L, Zhu J et al. Regulation of the oncoprotein KLF8 by a switch between acetylation and sumoylation. Am J Transl Res 2011; 3: 121-132.
33. Urvalek AM, Wang X, Lu H, Zhao J. KLF8 recruits the p300 and PCAF co-activators to its amino terminal activation domain to activate transcription. Cell Cycle 2010; 9: 601-611.
34. Wang X, Urvalek AM, Liu J, Zhao J. Activation of KLF8 transcription by focal adhesion kinase in human ovarian epithelial and cancer cells. J Biol Chem 2008; 283: 13934-13942.
35. Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev 2009; 28: 35-49.
36. Eaton SA, Funnell AP, Sue N, Nicholas H, Pearson RC, Crossley M. A network of Kruppel-like Factors (Klfs). Klf8 is repressed by Klf3 and activated by Klf1 in vivo. J Biol Chem 2008; 283: 26937-26947.
37. Lu H, Wang X, Li T, Urvalek AM, Yu L, Li J et al. Identification of poly (ADP-ribose) polymerase-1 (PARP-1) as a novel Kruppel-like factor 8-interacting and-regulating protein. J Biol Chem 2011; 286: 20335-20344.
38. Mehta TS, Lu H, Wang X, Urvalek AM, Nguyen KH, Monzur F et al. A unique sequence in the N-terminal regulatory region controls the nuclear localization of KLF8 by cooperating with the C-terminal zinc-fingers. Cell Res 2009; 19: 1098-1109.
39. Wang X, Zhao J. KLF8 transcription factor participates in oncogenic transformation. Oncogene 2007; 26: 456-461. (Pubitemid 46122835)
40. Fu WJ, Li JC, Wu XY, Yang ZB, Mo ZN, Huang JW et al. Small interference RNA targeting Kruppel-like factor 8 inhibits the renal carcinoma 786-0 cells growth in vitro and in vivo. J Cancer Res Clin Oncol 2010; 136: 1255-1265.
41. Liu L, Liu N, Xu M, Liu Y, Min J, Pang H et al. Lentivirus-delivered Kruppel-like factor 8 small interfering RNA inhibits gastric cancer cell growth in vitro and in vivo. Tumour Biol 2012; 33: 53-61.
42. Cox BD, Natarajan M, Stettner MR, Gladson CL. New concepts regarding focal adhesion kinase promotion of cell migration and proliferation. J Cell Biochem 2006; 99: 35-52.
43. Schnell O, Romagna A, Jaehnert I, Albrecht V, Eigenbrod S, Juerchott K et al. Kruppel-like factor 8 (KLF8) is expressed in gliomas of different WHO grades and is essential for tumor cell proliferation. PLoS One 2012; 7: e30429.
44. Wan W, Zhu J, Sun X, Tang W. Small interfering RNA targeting Kruppel-like factor 8 inhibits U251 glioblastoma cell growth by inducing apoptosis. Mol Med Report 2012; 5: 347-350.
45. Stegmeier F, Rape M, Draviam VM, Nalepa G, Sowa ME, Ang XL et al. Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities. Nature 2007; 446: 876-881.
46. Lahiri SK, Zhao J. Kruppel-like factor 8 emerges as an important regulator of cancer. Am J Transl Res 2012; 4: 357-363.
47. Evans PM, Liu C. Roles of Krupel-like factor 4 in normal homeostasis, cancer and stem cells. Acta Biochim Biophys Sin 2008; 40: 554-564. (Pubitemid 352009081)
48. Gumireddy K, Li A, Gimotty PA, Klein-Szanto AJ, Showe LC, Katsaros D et al. KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol 2009; 11: 1297-1304.
49. McConnell BB, Yang VW. Mammalian Kruppel-like factors in health and diseases. Physiol Rev 2010; 90: 1337-1381.
50. Suresh B, Ramakrishna S, Lee HJ, Choi JH, Kim JY, Ahn WS et al. K48-and K63-linked polyubiquitination of deubiquitinating enzyme USP44. Cell Biol Int. 2010; 34: 799-808.
51. Kang X, Sun L, Guo K, Shu H, Yao J, Qin X et al. Serum protein biomarkers screening in HCC patients with liver cirrhosis by ICAT-LC-MS/MS. J Cancer Res Clin Oncol 2010; 136: 1151-1159.
52. Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci USA 2012; 109: 9623-9628.
53. Yang T, Cai SY, Zhang J, Lu JH, Lin C, Zhai J et al. Kruppel-like factor 8 is a new wnt/beta-catenin signaling target gene and regulator in hepatocellular carcinoma. PLoS One 2012; 7: e39668.
54. Siegel PM, Shu W, Massague J. Mad upregulation and Id2 repression accompany transforming growth factor (TGF)-beta-mediated epithelial cell growth suppression. J Biol Chem 2003; 278: 35444-35450. (Pubitemid 37102314)
55. Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the human deubiquitinating enzyme interaction landscape. Cell 2009; 138: 389-403.